hoodb.com

藥華藥(6446)本公司Ropeginterferon alfa-2b(P1101)之原發性血小板過多症(ET)全球多國多中心第三期臨床試驗最後一位受試者完成試驗(11/12日股價622元)

|

You are leaving and open the following URL" of about "-7PM ET 12" news

news.google.com/rss/articles/CBMickFVX3lxTE8ydzROOXcwRllNZGIyVXF2Uk03NWxxUTlXVFRINlBlX2Iyb2R4QlVrYURjTFVlNlRoUTVsX2tUdlNJMjRrQWR4V2xUQlpwd3ZFZnpiQUgyNEk0U2ZSODFaS19xOC1OaURqUjlCSG9SQTkxdw?oc=5


Continue Opne >

-7PM ET 12: 藥華藥(6446)本公司Ropeginterferon alfa-2b(P1101)之原發性血小板過多症(ET)全球多國多中心第三期臨床試驗最後一位受試者完成試驗(11/12日股價622元)


More -7PM ET 12 news:



Warning: filemtime(): stat failed for aCache/aaa/gnews/PT/-7PM ET 12.xml in /var/www/hoodb/function.php on line 339
1736516083-
Warning: file_put_contents(aCache/aaa/gnews/PT//-7PM ET 12.xml): Failed to open stream: No space left on device in /var/www/hoodb/function.php on line 348

About -7PM ET 12

from
1736516083-1736280959

Warning: filemtime(): stat failed for aCache/search/pt/-7PM ET 12 in /var/www/hoodb/function.php on line 339
1736516083-

-7PM ET 12, 藥華藥(6446)本公司Ropeginterferon alfa-2b(P1101)之原發性血小板過多症(ET)全球多國多中心第三期臨床試驗最後一位受試者完成試驗(11/12日股價622元) 2022 -7PM ET 12

藥華藥(6446)本公司Ropeginterferon alfa-2b(P1101)之原發性血小板過多症(ET)全球多國多中心第三期臨床試驗最後一位受試者完成試驗(11/12日股價622元)

Choose Your Country or Region


Back to Top



藥華藥(6446)本公司Ropeginterferon alfa-2b(P1101)之原發性血小板過多症(ET)全球多國多中心第三期臨床試驗最後一位受試者完成試驗(11/12日股價622元)

Copyright © 2020-2021 hoodb.com. All Rights Reserved.